Funder
National Natural Science Foundation of China
state key laboratory of Pharmaceutical Biotechnology, Nan-jing University, China
Scientific Program of Henan Province
China Postdoctoral Science Foundation
Key Research Program of Higher Education of Henan Province
Zhengzhou University
Subject
Organic Chemistry,Drug Discovery,Pharmacology,General Medicine
Reference60 articles.
1. An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015);Ojha;Expert Opin. Ther. Pat.,2017
2. Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl Esters: toward the development of sulfonic acid prodrugs with peroral bioavailability;Yan;J. Med. Chem.,2004
3. Xanthinol nicotinate in peripheral vascular disease;Davis;Practitioner,1975
4. Drug monitoring study (phase IV) of xantinolnicotinate (Complamin) in general practice;Lehmann;Pharmacopsychiatry,1993
5. GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse;Toldo;J. Pharmacol. Exp. Therapeut.,2012
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献